Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

3-4 March 2017

Madrid, Spain

Scientific Agenda

Friday, 3 March 2017

08:20

Welcome and introduction
Giorgio V. Scagliotti, MD, PhD

Session I: Diagnosis, staging, and prevention of lung cancer

Moderators: Giorgio V. Scagliotti, MD, PhD and Luis Paz-Ares, MD, PhD

08:30

Pre-survey (Sessions I-II)

08:40

Updates on TNM staging system
Ramon Rami-Porta, MD

09:00

Interventional pulmonology: Using endobronchial and other techniques to optimize diagnosis and therapy in lung cancer
Stefano Gasparini, MD, FCCP

09:20

Updates on functional imaging in lung cancer
Speaker invited

09:40

Primary and secondary prevention of lung cancer
Ugo Pastorino, MD, PhD

10:00

Case-based panel discussion

10:30

Break

Session II: Debate: Optimal treatment strategy in stage III

Moderators: Ugo Pastorino, MD, PhD and Luis Paz-Ares, MD, PhD

10:45

Debate: Optimal approach for stage III NSCLC
Trimodality therapy: Paul Van Schil, MD
Bimodality therapy: Wilfried Eberhardt, MD

11:15

Post-survey (Sessions I-II)

11:20

Lunch Satellite Symposium
Presented by Elsevier; Supported by Lilly Oncology

Session III: New avenues in lung cancer: Focus on immunotherapy

Moderators: Giorgio V. Scagliotti, MD, PhD and Luis Paz-Ares, MD, PhD

13:20

Pre-survey (Sessions III-IV)

13:25

Basis for immunotherapy in lung cancer
Sandrine Aspeslagh, MD, PhD

13:45

Immune checkpoint inhibitors in lung cancer: Lights and shadows
Joachim G. Aerts, PhD

14:05

PDL-1 testing and other potential biomarkers for immunotherapy
Giorgio V. Scagliotti, MD, PhD

14:20

Beyond immune checkpoint inhibitors: Opportunities for combination approaches
Dario Sangiolo, MD

14:35

Managing adverse effects with immunotherapy
Jesus Corral, MD

14:50

Case-based panel discussion

15:05

Break

Session IV: Radiotherapy and lung cancer

Moderators: Umberto Ricardi, MD and Giorgio V. Scagliotti, MD, PhD

15:20

New radiotherapy techniques for the treatment of lung cancer
Suresh Senan, MRCP, FRCR, PhD

15:40

Treatment of brain metastases with loco-regional treatments
Umberto Ricardi, MD, PhD

15:55

Balancing toxicity and disease control in the evolution of radiotherapy technology
Philippe Lambin, MD, PhD

16:15

Case-based panel discussion

16:30

Post-survey (Sessions III-IV)

16:35

Adjourn
 

Saturday, 4 March 2017

08:20

Welcome and introduction
Luis Paz-Ares, MD, PhD

Session V: Oncogenic drivers in lung cancer

Moderator: Luis Paz-Ares, MD, PhD

08:30

Pre-survey (Sessions V-VII)

08:40

EGFR mutation positive tumors: Treatment strategies in front line and at relapse
Céline Mascaux, MD, PhD

09:00

ALK and ROS1 translocated tumors: Update on treatment strategies
Silvia Novello, MD, PhD

09:20

HER-2/BRAF/KRAS and MET
Luis Paz-Ares, MD, PhD

09:40

Case-based panel discussion

10:10

Break

Session VI: Debate: Liquid versus tissue biopsy

Moderators: Silvia Novello, MD, PhD and Luis Paz-Ares, MD, PhD

10:30

Debate: Liquid biopsy will replace tissue biopsy?
Yes: Thomas Newsom-Davis, BSc, PhD, FRCP
No: Fernando López-Ríos, MD, PhD

Session VII: Searching for optimized treatment strategies in lung cancer

Moderators: Egbert F. Smit, MD, PhD and Giorgio V. Scagliotti, MD, PhD

11:00

Mutation independent approaches in adenocarcinoma including maintenance
Sanjay Popat, PhD

11:20

Squamous cell carcinoma of the lung: Treatment options in first- and second line
Luis Paz-Ares, MD, PhD

11:40

New treatment opportunities for small cell lung cancer
Egbert F. Smit, MD, PhD

12:00

Post-survey (Sessions V-VII)

12:10

Lunch Break

Session VIII: Rare thoracic malignancies and special populations

Moderators: Luis Paz-Ares, MD, PhD and Paul Baas, MD

13:30

Pre-survey (Session VIII)

13:35

Carcinoids, large cell neuroendocrine carcinoma, thymoma and thymic carcinomas
Nicolas Girard, MD, PhD

13:55

New treatment avenues in malignant mesothelioma
Paul Baas, MD

14:15

Treatment of elderly and PS2 patients
Tanja Cufer, MD

14:35

Post-session audience survey (Session VIII)

14:40

Wrap up

14:50

Adjourn